Results 21 to 30 of about 789,217 (259)

Idiopathic pulmonary fibrosis [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2008
Idiopathic pulmonary fibrosis (IPF) is a non-neoplastic pulmonary disease that is characterized by the formation of scar tissue within the lungs in the absence of any known provocation. IPF is a rare disease which affects approximately 5 million persons worldwide.
Noble Paul W, Meltzer Eric B
openaire   +3 more sources

Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression [PDF]

open access: yes, 2010
Background A significant genetic component has been described for idiopathic pulmonary fibrosis (IPF). The R131H (rs1801274) polymorphism of the IgG receptor FcγRIIa determines receptor affinity for IgG subclasses and is associated with several chronic ...
Hart Simon P   +31 more
core   +2 more sources

Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis [PDF]

open access: yes, 2021
Fibrotic Interstitial lung diseases (ILDs) are complex disorders of variable clinical behaviour. The majority of them cause significant morbidity, whilst Idiopathic Pulmonary Fibrosis (IPF) is recognised as the most relentless.
Mastrodimou, Semeli   +19 more
core   +1 more source

Alveolar cells under mechanical stressed niche: critical contributors to pulmonary fibrosis

open access: yesMolecular Medicine, 2020
Pulmonary fibrosis arises from the repeated epithelial mild injuries and insufficient repair lead to over activation of fibroblasts and excessive deposition of extracellular matrix, which result in a mechanical stretched niche.
Juntang Yang   +3 more
doaj   +1 more source

Informal caregivers experience of supplemental oxygen in pulmonary fibrosis

open access: yesHealth and Quality of Life Outcomes, 2017
Background Patients prescribed supplemental oxygen (O2) therapy face challenges as they adjust to being constantly “tethered” to an oxygen delivery device.
Bridget A. Graney   +8 more
doaj   +1 more source

[Idiopathic pulmonary fibrosis].

open access: yesMedecine sciences : M/S, 2022
38;6 ...
Hennion, Nathan   +4 more
openaire   +6 more sources

Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events [PDF]

open access: yes, 2014
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival.
Per M. Hellström   +56 more
core   +1 more source

Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E-2 production [PDF]

open access: yes, 2004
Levels of prostaglandin E-2 (PGE(2)), a potent inhibitor of fibroblast function, are decreased in the lungs of patients with pulmonary fibrosis, which has been shown to be because of limited expression of cyclooxygenase-2 (COX-2).
Martyn L. Foster   +21 more
core   +1 more source

Cystic fibrosis related chronic liver disease: a study of its influence upon prognosis and possible mechanisms for this; with specific reference to pulmonary and systemic haemodynamics [PDF]

open access: yes, 1995
MDTo assess the influence of chronic liver disease on survival a time dependent multivariate Cox regression analysis was It performed. The results confirmed that patients with evidence of chronic liver disease have a worse prognosis.
Williams, Simon Graham John
core   +2 more sources

Obstructive sleep apnea and nocturnal hypoxemia in adult patients with cystic fibrosis

open access: yesBMC Pulmonary Medicine, 2022
Background Obstructive sleep apnea (OSA), nocturnal hypoxemia and excessive daytime sleepiness (EDS) are common comorbidities in people with cystic fibrosis (pwCF). Most of the data showing this originates from children and adolescents.
Matthias Welsner   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy